Patients with Graves disease in association with other autoimmune diseases had a 4-fold higher rate of transition from initial hypothyroidism to hyperthyroidism compared with patients who had isolated Graves disease.
Teprotumumab is an investigational fully human monoclonal antibody that works by inhibiting the insulin-like growth factor 1 receptor.
Teprotumumab effectively reduces proptosis in patients with active thyroid eye disease.
Early and intensive treatment for hyperthyroidism in Graves disease is associated with improvements in cardiovascular morbidity and all-cause mortality, regardless of treatment method used.
A patient with no thyroid-related symptoms presents with an abnormal thyroid function test.
Maternal Graves disease and Hashimoto disease during pregnancy increases childhood risk for type 1 diabetes and schizophrenia, respectively.
Investigators reviewed cases of patients with multiple sclerosis treated with alemtuzumab to determine the type and frequency of thyroid dysfunction.
Patients given teprotumumab were more likely to experience a response at 24 weeks vs placebo.
In a randomized, double-blind study, Rituximab was more effective in treating Graves’ orbitopathy than intravenous methylprednisolone.
Statins and thyroidectomy may delay or prevent thyroid-associated ophthalmopathy in Graves’ disease.
